{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:20:24Z","timestamp":1762658424908,"version":"3.37.3"},"reference-count":45,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T00:00:00Z","timestamp":1537228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European & Developing Countries Clinical Trials Partnership","doi-asserted-by":"crossref","award":["PACTR201105000291300"],"award-info":[{"award-number":["PACTR201105000291300"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["206379\/Z\/17\/Z"],"award-info":[{"award-number":["206379\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European & Developing Countries Clinical Trials Partnership","doi-asserted-by":"crossref","award":["PACTR201105000291300"],"award-info":[{"award-number":["PACTR201105000291300"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Research Foundation of South Africa","award":["95106","90729"],"award-info":[{"award-number":["95106","90729"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI068634","UM1 AI068636","UM1AI106701","U01 AI068632"],"award-info":[{"award-number":["UM1AI068634","UM1 AI068636","UM1AI106701","U01 AI068632"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["AI068632"],"award-info":[{"award-number":["AI068632"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/jac\/dky378","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T07:53:25Z","timestamp":1535615605000},"source":"Crossref","is-referenced-by-count":15,"title":["Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1685-4882","authenticated-orcid":false,"given":"Maxwell T","family":"Chirehwa","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dissou","family":"Affolabi","sequence":"additional","affiliation":[{"name":"National Programme for Tuberculosis and Pulmonary Diseases, Cotonou, Benin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oumou","family":"Bah-Sow","sequence":"additional","affiliation":[{"name":"Service de Pneumo-Phtisiologie, Hopital Ignace Deen, Conakry, Guinea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Merle","sequence":"additional","affiliation":[{"name":"London School of Hygiene & Tropical Medicine, London, UK"},{"name":"UNICEF\/UNDP\/World Bank\/WHO Special Programme on Research and Training in Tropical Diseases (TDR), Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"RAFA team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alimatou","family":"N\u2019Diaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahima Mari\u00e9tou","family":"Mbaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouke","family":"De Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Severin","family":"Anagonou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Diatema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahima Khalil","family":"Gomina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Severin","family":"Gossa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanche","family":"Tanimomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfried","family":"Bekou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Galperine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Furco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouctar","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boubacar","family":"Bah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falilou","family":"Bah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00e9n\u00e9","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdourahmane","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadjo","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamadou Telly","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aissatou Bah","family":"Sylla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpha Mamadou","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Sarr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nd\u00e9ye Fatou","family":"Ngom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kine","family":"Ndiaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diama","family":"Sakho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Ngom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatoumata","family":"Ba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amadou","family":"Seck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Furco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sian","family":"Floyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Branson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dany","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Oubaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Saint-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,9,18]]},"reference":[{"year":"2010","author":"World Health Organization","key":"key\n\t\t\t\t20180918110221_dky378-B1"},{"key":"key\n\t\t\t\t20180918110221_dky378-B2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180918110221_dky378-B3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1164\/ajrccm.156.3.9609132","article-title":"The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis","volume":"156","author":"Donald","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180918110221_dky378-B4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00228-007-0305-5","article-title":"The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid","volume":"63","author":"Donald","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180918110221_dky378-B5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF01086149","article-title":"Pharmacokinetics of isoniazid metabolism in man","volume":"4","author":"Ellard","year":"1976","journal-title":"J Pharmacokinet Biopharm"},{"key":"key\n\t\t\t\t20180918110221_dky378-B6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/cpt1976195part2610","article-title":"Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis","volume":"19","author":"Ellard","year":"1976","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180918110221_dky378-B7","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1164\/ajrccm.155.5.9154882","article-title":"Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis","volume":"155","author":"Parkin","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180918110221_dky378-B8","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1086\/424999","article-title":"The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid","volume":"39","author":"Donald","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180918110221_dky378-B9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/cis353","article-title":"Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy","volume":"55","author":"Pasipanodya","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180918110221_dky378-B10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.2011.03940.x","article-title":"Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients","volume":"72","author":"Wilkins","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180918110221_dky378-B11","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1128\/AAC.05526-11","article-title":"Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines","volume":"56","author":"McIlleron","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180918110221_dky378-B12","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1128\/AAC.02379-13","article-title":"Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment","volume":"58","author":"Bhatt","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180918110221_dky378-B13","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1128\/AAC.01345-13","article-title":"Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus","volume":"57","author":"Babalik","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"journal-title":"Division of Microbiology and Infectious Diseases Adult Toxicity Table","year":"2007","author":"National Institute of Allergy and Infectious Diseases","key":"key\n\t\t\t\t20180918110221_dky378-B14"},{"author":"World Health Organization","key":"key\n\t\t\t\t20180918110221_dky378-B15"},{"volume-title":"NONMEM Users\u2019 Guides (1989\u20132013)","year":"2013","author":"Beal","key":"key\n\t\t\t\t20180918110221_dky378-B16"},{"key":"key\n\t\t\t\t20180918110221_dky378-B17","doi-asserted-by":"crossref","first-page":"e50.","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"volume-title":"R: A Language and Environment for Statistical Computing","year":"2017","author":"R Core Team","key":"key\n\t\t\t\t20180918110221_dky378-B18"},{"volume-title":"RStudio: Integrated Development Environment for R","year":"2015","author":"RStudio Team","key":"key\n\t\t\t\t20180918110221_dky378-B19"},{"key":"key\n\t\t\t\t20180918110221_dky378-B20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2125.2004.02321.x","article-title":"A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction","volume":"59","author":"Gordi","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180918110221_dky378-B21","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/9780470087978.ch28","volume-title":"Pharmacometrics: The Science of Quantitative Pharmacology","author":"Frame","year":"2007"},{"key":"key\n\t\t\t\t20180918110221_dky378-B22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"59","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"key\n\t\t\t\t20180918110221_dky378-B23","doi-asserted-by":"crossref","first-page":"e0141002.","DOI":"10.1371\/journal.pone.0141002","article-title":"Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania","volume":"10","author":"Denti","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180918110221_dky378-B24","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","article-title":"Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies","volume":"34","author":"Savic","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"key\n\t\t\t\t20180918110221_dky378-B25","first-page":"267","volume-title":"Pharmacokinetics in Drug Development: Clinical Study Design and Analysis","author":"Zannikos","year":"2004"},{"key":"key\n\t\t\t\t20180918110221_dky378-B26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"key\n\t\t\t\t20180918110221_dky378-B27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"key\n\t\t\t\t20180918110221_dky378-B28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.510270305","article-title":"Hepatic plasma flow estimated according to Fick\u2019s principle in patients with hepatic encephalopathy: evaluation of indocyanine green and d-sorbitol as test substances","volume":"27","author":"Clemmesen","year":"1998","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20180918110221_dky378-B29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.17145\/jab.15.015","article-title":"Quantification of isoniazid, pyrazinamide and ethambutol in serum using liquid chromatography-tandem mass spectrometry","volume":"1","author":"Sturkenboom","year":"2015","journal-title":"J Appl Bioanal"},{"key":"key\n\t\t\t\t20180918110221_dky378-B30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00003495-199856060-00014","article-title":"Efavirenz","volume":"56","author":"Adkins","year":"1998","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20180918110221_dky378-B31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.apsb.2016.07.014","article-title":"Isoniazid metabolism and hepatotoxicity","volume":"6","author":"Wang","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"key\n\t\t\t\t20180918110221_dky378-B32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0041-3879(84)90079-5","article-title":"The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis","volume":"65","author":"Ellard","year":"1984","journal-title":"Tubercle"},{"key":"key\n\t\t\t\t20180918110221_dky378-B33","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1128\/AAC.01244-15","article-title":"Population pharmacokinetic analysis of isoniazid, acetyl-isoniazid, and isonicotinic acid in healthy volunteers","volume":"59","author":"Seng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180918110221_dky378-B34","first-page":"29","article-title":"Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms","volume":"9","author":"Hein","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key\n\t\t\t\t20180918110221_dky378-B35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00008571-200104000-00004","article-title":"Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms","volume":"11","author":"Fretland","year":"2001","journal-title":"Pharmacogenetics"},{"key":"key\n\t\t\t\t20180918110221_dky378-B36","doi-asserted-by":"crossref","first-page":"34519","DOI":"10.1074\/jbc.274.49.34519","article-title":"Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype","volume":"274","author":"Leff","year":"1999","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180918110221_dky378-B37","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cca.2005.08.012","article-title":"The influence of NAT2 genotypes on the plasma concentration of isoniazid and acetyl-isoniazid in Chinese pulmonary tuberculosis patients","volume":"365","author":"Chen","year":"2006","journal-title":"Clin Chim Acta"},{"key":"key\n\t\t\t\t20180918110221_dky378-B38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/17512433.2017.1246179","article-title":"The challenges of pharmacokinetic variability of first-line anti-TB drugs","volume":"10","author":"Devaleenal","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"key\n\t\t\t\t20180918110221_dky378-B39","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180918110221_dky378-B40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180918110221_dky378-B41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7742(08)00001-9","article-title":"Gender differences in pharmacological response","volume":"83","author":"Anderson","year":"2008","journal-title":"Int Rev Neurobiol"},{"key":"key\n\t\t\t\t20180918110221_dky378-B42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2004.02157.x","article-title":"What is the best size descriptor to use for pharmacokinetic studies in the obese?","volume":"58","author":"Green","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180918110221_dky378-B43","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1128\/AAC.00480-16","article-title":"HIV-1 coinfection does not reduce exposure to rifampin, isoniazid, and pyrazinamide in South African tuberculosis outpatients","volume":"60","author":"Rockwood","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180918110221_dky378-B44","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/0006-2952(91)90282-A","article-title":"N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans","volume":"42","author":"Hickman","year":"1991","journal-title":"Biochem Pharmacol"},{"key":"key\n\t\t\t\t20180918110221_dky378-B45","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/14622416.9.3.311","article-title":"Pharmacogenomics of anti-TB drugs-related hepatotoxicity","volume":"9","author":"Roy","year":"2008","journal-title":"Pharmacogenomics"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dky378\/25795309\/dky378.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T03:12:36Z","timestamp":1571800356000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dky378\/5101397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,18]]},"references-count":45,"URL":"https:\/\/doi.org\/10.1093\/jac\/dky378","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published":{"date-parts":[[2018,9,18]]}}}